Ardelyx, Inc. (ARDX) Stake Lifted by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lifted its position in shares of Ardelyx, Inc. (NASDAQ:ARDX) by 17.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,139 shares of the biopharmaceutical company’s stock after acquiring an additional 9,219 shares during the quarter. Goldman Sachs Group Inc. owned 0.13% of Ardelyx worth $312,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new position in shares of Ardelyx during the second quarter worth about $111,000. Dimensional Fund Advisors LP increased its stake in shares of Ardelyx by 280.7% during the second quarter. Dimensional Fund Advisors LP now owns 259,202 shares of the biopharmaceutical company’s stock worth $1,322,000 after acquiring an additional 191,121 shares during the period. Citadel Advisors LLC acquired a new position in shares of Ardelyx during the second quarter worth about $248,000. Parametric Portfolio Associates LLC increased its stake in shares of Ardelyx by 8.9% during the second quarter. Parametric Portfolio Associates LLC now owns 27,581 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 2,252 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Ardelyx by 3.9% during the second quarter. Vanguard Group Inc. now owns 1,277,634 shares of the biopharmaceutical company’s stock worth $6,516,000 after acquiring an additional 48,077 shares during the period. Institutional investors and hedge funds own 78.43% of the company’s stock.

Ardelyx, Inc. (NASDAQ:ARDX) opened at $5.70 on Friday. Ardelyx, Inc. has a 1 year low of $4.05 and a 1 year high of $16.30.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.10. During the same quarter last year, the business earned ($0.65) EPS. analysts anticipate that Ardelyx, Inc. will post -2.05 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/18/ardelyx-inc-ardx-stake-lifted-by-goldman-sachs-group-inc.html.

A number of brokerages have recently issued reports on ARDX. Cantor Fitzgerald set a $12.00 price target on shares of Ardelyx and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Zacks Investment Research upgraded shares of Ardelyx from a “sell” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Friday, November 10th. Leerink Swann restated an “outperform” rating and set a $13.00 target price on shares of Ardelyx in a research report on Tuesday, October 17th. Finally, ValuEngine lowered shares of Ardelyx from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $14.75.

In other news, COO Reginald Seeto sold 10,008 shares of the stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $5.20, for a total value of $52,041.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 15.47% of the company’s stock.

Ardelyx Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply